MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs.

@article{Leleu2013MELISSEAL,
  title={MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs.},
  author={Xavier Leleu and Philippe Rodon and Cyrille Hulin and Laurent Daley and Charles Dauriac and Maya Hacini and Olivier Decaux and Jean-Claude Eisemann and Olivier Fitoussi and Bruno Lioure and Laurent Voillat and Borhane Slama and Ahmad Al Jijakli and Riad Benramdane and Carinne Chaleteix and R. Ian Costello and Antoine Thyss and Claire Mathiot and Eileen M. Boyle and Fr{\'e}d{\'e}ric Maloisel and A. Stoppa and Brigitte Kolb and Mauricette Michallet and Anne Lamblin and Patrick Natta and Thierry Facon and Ismail Elalamy and Jean-Paul Fermand and Philippe Moreau},
  journal={Thrombosis and haemostasis},
  year={2013},
  volume={110 4},
  pages={
          844-51
        }
}
Immunomodulatory drugs (IMiDs) are associated with an increased risk of venous thromboembolism (VTE) in multiple myeloma (MM) patients. We designed MELISSE, a multicentre prospective observational study, to evaluate VTE incidence and identify risk factors in IMiDs-treated MM. Our objective was to determine the real-life practice of VTE prophylaxis strategy. A total of 524 MM patients were included, and we planned to collect information at baseline, at four and at 12 months, on MM therapy, on… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 21 CITATIONS